A
Andrea Zivi
Researcher at Imperial College London
Publications - 45
Citations - 5017
Andrea Zivi is an academic researcher from Imperial College London. The author has contributed to research in topics: Prostate cancer & Abiraterone acetate. The author has an hindex of 15, co-authored 39 publications receiving 4519 citations. Previous affiliations of Andrea Zivi include The Royal Marsden NHS Foundation Trust & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono,Christopher J. Logothetis,Arturo Molina,Karim Fizazi,Scott North,Luis Chu,Kim N. Chi,Robert Jones,Oscar B. Goodman,Fred Saad,John Staffurth,Paul N. Mainwaring,S. J. Harland,Thomas W. Flaig,Thomas E. Hutson,Tina Cheng,Helen Patterson,John D. Hainsworth,Charles J. Ryan,Cora N. Sternberg,Susan Ellard,Aude Flechon,Mansoor N. Saleh,Mark C. Scholz,Eleni Efstathiou,Andrea Zivi,Diletta Bianchini,Yohann Loriot,Nicole Chieffo,Thian Kheoh,Christopher M. Haqq,Howard I. Scher +31 more
TL;DR: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy.
Journal ArticleDOI
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
J. Mezynski,Carmel Pezaro,Diletta Bianchini,Andrea Zivi,Shahneen Sandhu,Emilda Thompson,Joanne Hunt,E. Sheridan,Bindumalini Rao Baikady,A. Sarvadikar,G. Maier,Alison Reid,A. Mulick Cassidy,David Olmos,Gerhardt Attard,J.S. de Bono +15 more
TL;DR: The activity of docetaxel post-abiraterone appears lower than anticipated and no responses to docetAXel were observed in abirater one-refractory patients.
Journal ArticleDOI
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Diletta Bianchini,David Lorente,Alejo Rodriguez-Vida,Aurelius Omlin,Carmel Pezaro,Roberta Ferraldeschi,Andrea Zivi,Gerhardt Attard,Simon Chowdhury,J.S. de Bono +9 more
TL;DR: Preliminary case series data suggest limited activity of enzalutamide in the post-docetaxel and post-abiraterone patient population.
Journal ArticleDOI
The changing therapeutic landscape of castration-resistant prostate cancer
TL;DR: A treatment pathway for patients with CRPC is proposed and strategies to optimize the use of these agents are considered, including the incorporation of predictive and intermediate end point biomarkers, such as circulating tumor cells.
Journal ArticleDOI
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Sabine Schmid,Sabine Schmid,Aurelius Omlin,Celestia S. Higano,Christopher Sweeney,Nieves Martinez Chanza,Niven Mehra,Malou C.P. Kuppen,Malou C.P. Kuppen,Himisha Beltran,Himisha Beltran,Vincenza Conteduca,Daniel Vargas Pivato de Almeida,Fernando C. Maluf,William Oh,Che-Kai Tsao,Oliver Sartor,Elisa Ledet,Giuseppe Di Lorenzo,Steven Yip,Kim N. Chi,Diletta Bianchini,Ugo De Giorgi,Aaron R. Hansen,Tomasz M. Beer,Pernelle Lavaud,Rafael Morales-Barrera,Marcello Tucci,Elena Castro,Kostas Karalis,Andries M. Bergman,Mo Linh Le,Ursina Zürrer-Härdi,Carmel Pezaro,Hiroyoshi Suzuki,Andrea Zivi,Dirk Klingbiel,Sämi Schär,Silke Gillessen +38 more
TL;DR: In a case series of 508 patients, platinum-based therapy was associated with antitumor activity, especially among patients with known DNA repair gene aberrations.